Match!

Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity.

Published on Dec 1, 2000in Diabetes7.20
· DOI :10.2337/diabetes.49.12.2087
Melvin K. Dea9
Estimated H-index: 9
,
G W Van Citters2
Estimated H-index: 2
+ 3 AuthorsRichard N. Bergman103
Estimated H-index: 103
Cite
Abstract
Troglitazone is an antidiabetic agent that improves the ability of adipocytes to store triglycerides by enhancing their insulin sensitivity. Although potent in insulin-resistant states, the effect of troglitazone on lipid and glucose turnover in normal animals has not been assessed. Euglycemic clamps were performed as an insulin dose response in normal mongrel dogs (n = 6). Somatostatin was infused without hormone replacement (zero insulin) for 90 min. Insulin was then either portally replaced (1.8 pmol x min(-1) x kg(-1), overreplaced (5.4 pmol x min(-1) x kg(-1)), or overreplaced peripherally to match the systemic levels of the portal overreplacement dose (2.3 pmol x min(-1) x kg(-1)) for 180 min. A total of 600 mg troglitazone was then given orally each day for 3 weeks and continued throughout a second experimental phase, at which point the euglycemic clamps were repeated. In concordance with previous studies, endogenous glucose production (EGP) was similar whether insulin was delivered portally or peripherally, both before and during troglitazone treatment. Although free fatty acids (FFAs) at zero insulin were not affected, there was a leftward shift of the insulin-FFA dose response curve secondary to a suppression of FFA release into plasma. EGP was paradoxically elevated by troglitazone treatment because of an elevation of both gluconeogenesis and glycogenolysis. In conclusion, troglitazone reduced hepatic sensitivity to FFAs. Because EGP is a primary determinant of fasting blood glucose, we hypothesize that a protective mechanism exists in normal animals, preventing hypoglycemia during insulin sensitization with troglitazone.
  • References (23)
  • Citations (5)
Cite
References23
Newest
#1Marilyn Ader (SC: University of Southern California)H-Index: 28
#2Joyce M. Richey (SC: University of Southern California)H-Index: 16
Last.Richard N. Bergman (SC: University of Southern California)H-Index: 103
view all 3 authors...
#1David G. Maggs (Yale University)H-Index: 9
#2Thomas A. Buchanan (SC: University of Southern California)H-Index: 70
Last.Jerrold M. Olefsky (UCSD: University of California, San Diego)H-Index: 106
view all 10 authors...
#1Didier Auboeuf (French Institute of Health and Medical Research)H-Index: 32
#2Jennifer Rieusset (French Institute of Health and Medical Research)H-Index: 33
Last.Hubert Vidal (French Institute of Health and Medical Research)H-Index: 69
view all 10 authors...
Cited By5
Newest
#1Richard N. Bergman (SC: University of Southern California)H-Index: 103
#2Gregg W. Van Citters (SC: University of Southern California)H-Index: 8
Last.Martin Ellmerer (SC: University of Southern California)H-Index: 25
view all 7 authors...
View next paperMetabolic effects of troglitazone on fat-induced insulin resistance in the rat.